LLY

735.02

+1.26%↑

JNJ

177.01

-0.32%↓

ABBV

210.01

+0.49%↑

UNH

330.34

+3.53%↑

NVO

53.02

-2.79%↓

LLY

735.02

+1.26%↑

JNJ

177.01

-0.32%↓

ABBV

210.01

+0.49%↑

UNH

330.34

+3.53%↑

NVO

53.02

-2.79%↓

LLY

735.02

+1.26%↑

JNJ

177.01

-0.32%↓

ABBV

210.01

+0.49%↑

UNH

330.34

+3.53%↑

NVO

53.02

-2.79%↓

LLY

735.02

+1.26%↑

JNJ

177.01

-0.32%↓

ABBV

210.01

+0.49%↑

UNH

330.34

+3.53%↑

NVO

53.02

-2.79%↓

LLY

735.02

+1.26%↑

JNJ

177.01

-0.32%↓

ABBV

210.01

+0.49%↑

UNH

330.34

+3.53%↑

NVO

53.02

-2.79%↓

Search

Design Therapeutics Inc

Uždarymo kaina

5.77 -5.1

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

5.77

Max

6.27

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-1.4M

-19M

Pelno marža

-2,321.599

Darbuotojai

57

EBITDA

-1.3M

-22M

Rekomendacijos

By TipRanks

Rekomendacijos

Neutralu

12 mėnesių prognozė

-22.48% downside

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

90M

315M

Ankstesnė atidarymo kaina

10.87

Ankstesnė uždarymo kaina

5.77

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

Design Therapeutics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-09-08 23:59; UTC

Įsigijimai, susijungimai, perėmimai

Anglo American Is in Talks to Buy Teck Resources, Bloomberg Says

2025-09-08 22:02; UTC

Pagrindinės rinkos jėgos

Microsoft Signs $17.4 Billion AI Deal With Nebius

2025-09-08 17:01; UTC

Pagrindinės rinkos jėgos

Eightco Holdings Stock Surges as Dan Ives Joins Board Amid Crypto Push

2025-09-08 17:01; UTC

Pagrindinės rinkos jėgos

Tron Shares Rise After New Investment From Bravemorning

2025-09-08 16:14; UTC

Pagrindinės rinkos jėgos

Beyond Air Shares Climb on FDA Orphan Drug Designation for Brain Cancer Treatment

2025-09-08 16:13; UTC

Pagrindinės rinkos jėgos

Dianthus Shares Whipsaw on Strong Trial Results, Safety Concerns

2025-09-08 23:12; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-09-08 23:12; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2025-09-08 23:12; UTC

Rinkos pokalbiai

Infratil's New Bull Likes Exposure to Growing Infrastructure Businesses -- Market Talk

2025-09-08 22:56; UTC

Rinkos pokalbiai

Worst May Be Over for New Zealand Retailers -- Market Talk

2025-09-08 22:23; UTC

Rinkos pokalbiai

Ebos's Near-Term Earnings Outlook Dims -- Market Talk

2025-09-08 21:51; UTC

Rinkos pokalbiai

AT&T Backs Outlook After EchoStar Spectrum Purchase -- Market Talk

2025-09-08 21:47; UTC

Pagrindinės rinkos jėgos

Microsoft Signs $17.4B AI Deal With Nebius

2025-09-08 21:33; UTC

Įsigijimai, susijungimai, perėmimai

This Quantum Pure Play Is Going Public. What Infleqtion Does Differently, Says Its CEO. -- Barrons.com

2025-09-08 21:20; UTC

Įsigijimai, susijungimai, perėmimai

MEG Energy Plans to Respond on or Before Sept 15 >MEG.T

2025-09-08 21:19; UTC

Įsigijimai, susijungimai, perėmimai

MEG Energy Special Committee and Board Will Evaluate Revised Strathcona Offer >MEG.T

2025-09-08 21:18; UTC

Įsigijimai, susijungimai, perėmimai

MEG Energy Acknowledges Strathcona's Intention to Revise Offer

2025-09-08 20:50; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Tech, Media & Telecom Roundup: Market Talk

2025-09-08 19:33; UTC

Rinkos pokalbiai

Oil Futures Gain Despite Planned OPEC+ Output Increases -- Market Talk

2025-09-08 19:22; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Settle Higher -- Market Talk

2025-09-08 19:02; UTC

Rinkos pokalbiai

Dollar Lukewarm Amid Data Hiatus Ahead of August CPI -- Market Talk

2025-09-08 18:24; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-09-08 18:24; UTC

Rinkos pokalbiai

Weaker Argentine Peso Profitable for Grain Producers -- Market Talk

2025-09-08 17:29; UTC

Rinkos pokalbiai

Mexican Inflation Seen Little Changed in August -- Market Talk

2025-09-08 16:59; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

SpaceX Spectrum Acquisition Will Create More Satellite Connection Supply, Verizon CEO Says -- Market Talk

2025-09-08 16:36; UTC

Rinkos pokalbiai

Crude Futures Hold Gains After OPEC+ Output Decision -- Market Talk

2025-09-08 16:20; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

2025-09-08 16:16; UTC

Uždarbis

Strategy Stock May Not Ever Make It Into the S&P 500 Index -- Barrons.com

2025-09-08 16:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2025-09-08 16:04; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

Akcijų palyginimas

Kainos pokytis

Design Therapeutics Inc Prognozė

Kainos tikslas

By TipRanks

-22.48% į apačią

12 mėnesių prognozė

Vidutinis 5 USD  -22.48%

Aukščiausias 5 USD

Žemiausias 5 USD

Remiantis 2 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Design Therapeutics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Neutralu

2 ratings

0

Pirkti

2

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

3.26 / 3.63Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Very Strong Bearish Evidence

Vidutinės trukmės periodas

Bearish Evidence

Ilgalaikis periodas

Bearish Evidence

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Design Therapeutics Inc

Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.
help-icon Live chat